ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2011
Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR TS.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Structured self monitoring of blood glucose in Iranian people with type 2 diabetes; A cost consequence analysis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study assessed the cost efficacy and cost utility of the automatic blood glucose meter CONTOUR(®) TS from the public payer (National Health Fund [NHF]) and payer (patient and NHF) perspectives over a 26-year analysis horizon.
methodsClinical effectiveness data were obtained from prior clinical studies of automatic versus manually coded blood glucose meters. Cost data were obtained from the NHF. The probability of procedure use related to diabetic complications was obtained from four medical centers in Poland. The incremental cost-effectiveness ratio related to 1 life year gained and the incremental cost-utility ratio related to 1 quality-adjusted life year gained were calculated.
resultsAssuming co-funding from public funds, introduction of the CONTOUR(®) TS is associated with savings of Polish zloty (PLN) 31,846.19 (€ 8916.93) and PLN 113,018.19 (€ 31,645.09) per life year gained from the payer and public payer perspectives, respectively. Cost utility analyses showed that the CONTOUR(®) TS is associated with savings of PLN 40,465.59 (€ 11,330.37) and PLN 11,434.82 (€ 3201.75) per quality-adjusted life year gained from the payer and the public payer perspectives, respectively.
conclusionThe CONTOUR(®) TS appears superior to manually coded meters available in Poland both from the payer and the public payer perspectives and may represent an improved strategy for glycemic control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.